BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29224713)

  • 21. A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity.
    Manjili MH
    Adv Cancer Res; 2018; 137():17-36. PubMed ID: 29405975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
    Joshi M; Pal SK; Drabick JJ
    Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer immunotherapy - a promising approach.
    Gyles C
    Can Vet J; 2018 Aug; 59(8):825-827. PubMed ID: 30104771
    [No Abstract]   [Full Text] [Related]  

  • 24. Vaccine studies demonstrate promise of immunotherapy to treat breast cancer and prevent recurrence.
    Oncology (Williston Park); 2000 Oct; 14(10):1415-6. PubMed ID: 11098507
    [No Abstract]   [Full Text] [Related]  

  • 25. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
    Paliard X; Rixe O
    Target Oncol; 2019 Dec; 14(6):631-637. PubMed ID: 31595386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translating Science into Survival: Report on the Fifth International Cancer Immunotherapy Conference.
    Diken M; Kepp O; Brodsky AN
    Cancer Immunol Res; 2020 Jan; 8(1):3-6. PubMed ID: 31909729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status and future prospects of peptide-based cancer vaccines.
    Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
    Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic immunotherapy for cancer.
    Elmslie RE; Dow SW
    Semin Vet Med Surg Small Anim; 1997 Aug; 12(3):193-205. PubMed ID: 9283245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunological tumor therapy].
    Dietrich K; Theobald M
    Internist (Berl); 2015 Aug; 56(8):907-16; quiz 917. PubMed ID: 26187335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy of cancer: from vision to standard clinical practice.
    Huber CH; Wölfel T
    J Cancer Res Clin Oncol; 2004 Jul; 130(7):367-74. PubMed ID: 15067541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells.
    Kim SJ; Ha GH; Kim SH; Kang CD
    Immunol Invest; 2014; 43(6):517-34. PubMed ID: 24295450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor immunology top 10 list.
    Finn OJ
    Immunol Rev; 2008 Apr; 222():5-8. PubMed ID: 18363991
    [No Abstract]   [Full Text] [Related]  

  • 34. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach.
    Joshi B; Wang X; Banerjee S; Tian H; Matzavinos A; Chaplain MA
    J Theor Biol; 2009 Aug; 259(4):820-7. PubMed ID: 19446568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer Immunotherapy and endocrinology: A new opportunity for multidisciplinary collaboration.
    Zafon Llopis C
    Endocrinol Diabetes Nutr; 2017 Nov; 64(9):461-463. PubMed ID: 29050701
    [No Abstract]   [Full Text] [Related]  

  • 37. Dendritic cell immunotherapy: mapping the way.
    Figdor CG; de Vries IJ; Lesterhuis WJ; Melief CJ
    Nat Med; 2004 May; 10(5):475-80. PubMed ID: 15122249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple-purpose immunotherapy for cancer.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Biomed Pharmacother; 2015 Dec; 76():24-9. PubMed ID: 26653546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.
    Mick R; Chen TT
    Cancer Immunol Res; 2015 Dec; 3(12):1292-8. PubMed ID: 26644449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanomedicine and cancer immunotherapy - targeting immunosuppressive cells.
    Torres Andón F; Alonso MJ
    J Drug Target; 2015; 23(7-8):656-71. PubMed ID: 26453162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.